drugset / Trial / NCT01606436

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

NCT01606436

Phase 1 Completed 86 enrolled Denovo Biopharma LLC
RandomizedCrossoverDouble-blindBasic science

Summary

This study determined if a single dose of LY2140023 (pomaglumetad methionil) affects the electrical activity in the heart in participants with schizophrenia. This study also helped determine how a single high dose of LY2140023 is tolerated by participants.

Timeline

Start
2012-06
Primary completion
2012-08
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2140023 Unknown 400 mg Oral
Subject Moxifloxacin Small molecule 400 mg Oral

Indications